News Overview News Stock Info Analyst Coverage Stock Quote Stock Chart Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Compositon Resources Investor Email Alerts Investor Contacts Presentations Overview News Stock Info Analyst Coverage Stock Quote Stock Chart Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Compositon Resources Investor Email Alerts Investor Contacts Presentations Select Year : 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 Select Category : All Regulatory Non Regulatory Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months Sep 22, 2025 Read more Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 Sep 17, 2025 Read more Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer Aug 26, 2025 Read more Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships Aug 15, 2025 Read more Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization Jul 15, 2025 Read more Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer Jul 07, 2025 Read more Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic Jun 30, 2025 Read more Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer Jun 27, 2025 Read more Allarity Therapeutics Announces Changes to Board of Directors Jun 11, 2025 Read more Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action Jun 04, 2025 Read more Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer Jun 02, 2025 Read more Allarity Therapeutics Announces Participation in Pharma Partnering Summit US May 12, 2025 Read more Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment May 09, 2025 Read more Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025 Apr 25, 2025 Read more Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update Mar 31, 2025 Read more Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares Mar 24, 2025 Read more Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology Mar 17, 2025 Read more Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission Mar 13, 2025 Read more Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration Mar 06, 2025 Read more Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program Mar 03, 2025 Read more Quick Links SEC Filings IR Contact [email protected] Investor Email Alerts
